No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US OptionsDetailed Quotes
EOLS241220C12500
- 0.05
- -0.85-94.44%
15min DelayClose Dec 20 16:00 ET
0.05High0.05Low
0.05Open0.90Pre Close20 Volume31 Open Interest12.50Strike Price100.00Turnover4638.38%IV15.24%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier-1DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type0.0986Delta0.1551Gamma217.80Leverage Ratio-53.0341Theta0.0000Rho21.48Eff Leverage0.0000Vega
Intraday
- 5D
- Daily
News
Evolus, Inc.'s (NASDAQ:EOLS) Path To Profitability
Analysts Offer Insights on Healthcare Companies: Evolus (EOLS), Ultragenyx Pharmaceutical (RARE) and Henry Schein (HSIC)
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Express News | Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Evolus (NASDAQ:EOLS) Is Carrying A Fair Bit Of Debt
US Manufacturing Index Rises To 43, Highest Since 2020